Commerce Bank Makes New Investment in Revvity Inc. $RVTY

Commerce Bank acquired a new stake in Revvity Inc. (NYSE:RVTY) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 9,288 shares of the company’s stock, valued at approximately $1,033,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. CYBER HORNET ETFs LLC bought a new position in shares of Revvity in the 2nd quarter worth $32,000. Ascentis Independent Advisors acquired a new stake in Revvity in the 1st quarter valued at $29,000. MUFG Securities EMEA plc bought a new stake in Revvity during the 2nd quarter valued at $34,000. Global Retirement Partners LLC bought a new stake in Revvity during the 2nd quarter valued at $51,000. Finally, Headlands Technologies LLC acquired a new position in Revvity during the second quarter worth $49,000. Institutional investors own 86.65% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on RVTY shares. Barclays raised their price objective on shares of Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Stifel Nicolaus lowered their target price on shares of Revvity from $110.00 to $100.00 and set a “hold” rating on the stock in a report on Wednesday, May 6th. JPMorgan Chase & Co. dropped their price target on shares of Revvity from $96.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Sanford C. Bernstein assumed coverage on Revvity in a research note on Friday, June 26th. They set a “market perform” rating and a $115.00 price target for the company. Finally, TD Cowen reissued a “buy” rating on shares of Revvity in a report on Wednesday, July 15th. Three analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $108.36.

Revvity Price Performance

RVTY opened at $126.31 on Thursday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50. The company has a market capitalization of $14.09 billion, a price-to-earnings ratio of 60.15, a P/E/G ratio of 2.27 and a beta of 1.07. The firm’s fifty day moving average price is $112.94 and its two-hundred day moving average price is $100.82. Revvity Inc. has a 1 year low of $81.22 and a 1 year high of $126.90.

Revvity (NYSE:RVTY) last announced its earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, beating the consensus estimate of $1.21 by $0.20. The company had revenue of $729.69 million during the quarter, compared to the consensus estimate of $702.96 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The firm’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts anticipate that Revvity Inc. will post 5.36 earnings per share for the current fiscal year.

Revvity Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be given a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd. Revvity’s dividend payout ratio is presently 13.33%.

Revvity Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.